ASH: Pfizer’s Hemophilia A Gene Therapy May Have Slight Liver Safety Advantage

More Data Needed For Longer-Term Effects

 
• By Mandy Jackson
  
Pfizer presented the Phase III AFFINE data for its hemophilia A gene therapy at ASH (Alaric DeArment, /Scrip)

More from ASH

More from Therapy Areas